The background is a solid light yellow color. In the bottom-left and top-right corners, there are illustrations of yellow peonies. The flowers are rendered with detailed, layered petals, and the leaves are dark green with prominent veins. The overall aesthetic is clean and modern.

Numinus

Developing & delivering psychedelic therapies
to help people heal and be well

TSX.V:NUMI
OTC:LKYSF

April 2021

Forward Looking Statements

This presentation contains forward-looking statements within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, are “forward-looking statements.” Forward-looking statements can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward looking statements. Such risks and uncertainties include, among others, dependence on obtaining and maintaining regulatory approvals, including acquiring and renewing federal, provincial, municipal, local or other licenses and any inability to obtain all necessary governmental approvals licenses and permits to operate and expand the Company’s facilities; engaging in activities which currently are illegal under Canadian federal law and the uncertainty of existing protection from Canadian federal or other prosecution; regulatory or political change such as changes in applicable laws and regulations, including federal and provincial legalization, due to inconsistent public opinion, perception of the medical-use and adult-use marijuana industry as well as the use of psychedelic therapies, bureaucratic delays or inefficiencies or any other reasons; any other factors or developments which may hinder market growth; the Company’s limited operating history and lack of historical profits; reliance on management; the Company’s requirements for additional financing, and the effect of capital market conditions and other factors on capital availability, including closing of the financings contemplated herein; competition, including from more established or better financed competitors; and the need to secure and maintain corporate alliances and partnerships, including with customers and suppliers. These factors should be considered carefully, and readers are cautioned not to place undue reliance on such forward-looking statements. Although the Company has attempted to identify important risk factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other risk factors that cause actions, events or results to differ from those anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking statements. The Company has no obligation to update any forward-looking statement, even if new information becomes available as a result of future events, new information or for any other reason except as required by law.

N

Bringing psychedelics to the mainstream.



Unmet Need

Mental health is a \$100B+ industry,¹ and current treatments are often costly and ineffective

Breakthrough Potential

Psychedelics are becoming more accepted, validated by academic and industry research, and recognized by Canadian, US regulators

N

Competitive Edge

Involved in all stages of bringing safe, effective psychedelic-assisted therapies to market, from supply to patient delivery

N

Grounded in Safety and Science

Medical, research and clinical experts, supported by renowned advisors, drive industry firsts

N

Deep Moat

High barriers to entry—reinforced by IP, proprietary protocols, medical expertise, strategic partnerships, regulatory relationships and holistic, integrated approach to market leadership

N

Growth Platform

Well-funded and revenue-generating to advance business, acquisition and service rollout strategy

1. Canaccord Genuity, 'Around the Corner', May 2020

A Global Epidemic & Failing System of Mental Health Care



1 in 11 Canadians
will have PTSD in their lifetime¹



1 in 5 Canadians
suffer from addiction²



971 Million People
worldwide suffer from a mental or substance use disorder³



Inadequate Medications

Current options may have limited benefits, poor uptake, negative side effects and require chronic use



Adverse Drug Events

There are 80,000+ emergency department psychiatric drug adverse events in the U.S. per year⁴



Increasing Mortality

Some medications are associated with addiction and death



Overdose Deaths Rising

Reported deaths from US drug overdose reached an all-time high of almost 72,000 in 2019, with opioids involved in more than two-thirds of total deaths⁵



COVID-19 Mental Health Crisis

United Nations: A mental illness crisis looms as millions worldwide are surrounded by death and disease and forced into isolation, poverty and anxiety⁶



COVID-19 Drives Distress

PEW Research Centre, March 2021: 21% of U.S adults are experiencing high levels of psychological distress, including 32% aged 18-29 and 31% with low incomes⁷

1. "Substance use and addiction", *Canadian Mental Health Association*, <https://ontario.cmha.ca/addiction-and-substance-use-and-addiction/>.

2. "Traumatic Stress Section: Facts About Traumatic Stress and PTSD", *Canadian Psychological Association*, <https://cpa.ca/sections/traumaticstress/simplefacts/>.

3. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet*. 2018 Nov 10;392(10159):1789-1858.

4. Emergency department visits by adults for psychiatric medication adverse events. *JAMA Psychiatry*. 2014 Sep;71(9):1006-14. doi: 10.1001/jamapsychiatry.2014.436.

5. *The Lancet*, Volume 396, Issue 10259, P1316-1318, October 24, 2020.

6. Reuters, May 14, 2020.

7. PEW Research Centre, Survey of US Adults conducted Feb 16-21, 2021.

Paradigm shift

Psychedelic therapies increasingly demonstrate efficacy—from psilocybin relieving major depression with four times the efficacy of traditional antidepressants¹ to MDMA for PTSD showing both substantial clinical impact and potential cost-savings of millions of dollars per year.²

Breakthrough for Trauma Treatment: Safety and Efficacy of MDMA-Assisted Psychotherapy Compared to Paroxetine and Sertraline

Allison A. Feduccia¹, Lisa Jerome^{1*}, Berra Yazar-Klosinski², Amy Emerson³, Michael C. Mithoefer⁴ and Rick Doblin⁵

¹Department of Research Development and Regulatory Affairs, MAPS Public Benefit Corporation, Santa Cruz, CA, United States; ²Multidisciplinary Association for Psychedelic Studies, Santa Cruz, CA, United States; ³MAPS Public Benefit Corporation, Santa Cruz, CA, United States; ⁴Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC, United States

November 4, 2020

Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder A Randomized Clinical Trial

Alan K. Davis, PhD^{1,2}; Frederick S. Barrett, PhD¹; Darrick G. May, MD¹; [et al](#)

[> Author Affiliations](#) | [Article Information](#)

JAMA Psychiatry. Published online November 4, 2020. doi:10.1001/jamapsychiatry.2020.3285

RESEARCH ARTICLE

The cost-effectiveness of MDMA-assisted psychotherapy for the treatment of chronic, treatment-resistant PTSD

Elliot Marseille^{1,2*}, James G. Kahn², Berra Yazar-Klosinski³, Rick Doblin³

¹ Health Strategies International, Oakland, California, United States of America, ² University of California, San Francisco, California, United States of America, ³ Multidisciplinary Association for Psychedelic Studies (MAPS), Santa Cruz, California, United States of America

1. Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder. *JAMA Psychiatry*. 4 Nov 2020. doi:10.1001/jamapsychiatry.2020.3285.

2. The cost-effectiveness of MDMA-assisted psychotherapy for the treatment of chronic, treatment-resistant PTSD. *PLOS ONE*. 14 Oct 2020. <https://doi.org/10.1371/journal.pone.0239997>.

The Tide is Turning



2018

FDA begins to recognize 'breakthrough therapy' status



MDMA for PTSD



Synthetic psilocybin for Treatment-Resistant Disorder



Synthetic psilocybin for Major Depressive Disorder

2019

Imperial College London and Johns Hopkins open world's first psychedelic research centres

Aug 2020

Health Canada begins approving psilocybin therapy for select patients with terminal illness

Nov 2020

Oregon legalizes psilocybin mushrooms for use in therapy

Dec 2020

Health Canada proposes federal regulatory revision to allow controlled psychedelic access outside of clinical trials

Feb 2021

California proposes to decriminalize psychedelics

Feb 2021

Missouri Congressman proposes Right to Try bill to allow prescribed access for seriously ill patients to various psychedelics, including LSD, MDMA and psilocybin

Mar 2021

Washington, DC Initiative 81 allows DC residents to use plant and fungi medicines without fear of being investigated, arrested or jailed

Market Opportunity



\$16T

Cost of inaction on mental health crisis by 2030¹

\$2.5T-\$8.5T

Lost economic output due to mental, neurological and substance use disorders, annual global²

\$100B+

Total addressable market for mental health, annual global³

1. Lancet Commission on Global Mental Health and Sustainable Development, 2018

2. "Mental Health", World Bank, <https://www.worldbank.org/en/topic/mental-health>

3. Canaccord Genuity, 'Around the Corner', May 2020

An Integrated Health and Business Model for Healing at Scale

Numinus Bioscience


- ❑ Health Canada-licensed lab
- ❑ Develops therapeutics
- ❑ Offers contract services
- ❑ Supplies many key psychedelics to Canadian and export markets
- ❑ Generates IP

Numinus R&D

- ❑ Develops proprietary therapeutic treatment protocols for full range of mental disorders
- ❑ Investigating psychedelic substances including ketamine, MDMA and psilocybin
- ❑ Active with leading research partners including contract research organizations and MAPS (US)
- ❑ Leads implementation science to drive practice, policy and evidence

Numinus Health

- ❑ Delivers safe and effective psychedelic assisted psychotherapy with ketamine
- ❑ Provides additional mental health services through clinics and virtual services
- ❑ Provides expert therapists and physical infrastructure to drive implementation



Numinus Bioscience

Develops therapeutics as part of an applied research agenda, with IP advantages

Our assets

- ❑ Health Canada-licenced lab and industry-leading analytical equipment, operating *since 2012* with **history of botanical extraction**
- ❑ Canada's first licence by a pubco to cultivate and extract from psilocybin-producing mushrooms
- ❑ Federal licence to all the possession, production, assembly, sale, export and delivery of a wide variety of psychedelics including Ketamine, LSD, Mescaline, N,N-Dimethyltryptamine (DMTO), MDMA, Psilocin and Psilocybin
- ❑ Expert advisory board

Our progress

- ❑ Canada's **first successful harvest and extraction**
- ❑ Mushroom cultivation and extraction for therapeutics research
- ❑ Actively developing **IP**
- ❑ Providing psychedelic contract lab services for **revenue generation**
- ❑ Strong industry and regulatory relationships
- ❑ 7,500-square-foot expansion by end of 2021

Industry barriers to entry

- ❑ Complex, mandatory licencing for psychedelic research
- ❑ Limited supply of qualified researchers, state-of-the-art technology and specialized equipment



Numinus R&D

Develops safe, evidence-based clinical protocols under medical leadership, in concert with regulators and research partners

Our assets

- ❑ Medical team specially trained to integrate psychedelics into clinical care in real world settings
- ❑ Medical leadership with record in collaborating with regulators to drive advocacy and policy change
- ❑ Clinical research leadership with >500 peer-reviewed publications
- ❑ Deep experience with clinical guideline development and knowledge translation into real-world settings
- ❑ Compassionate access trials underway for both MDMA and psilocybin

Our progress

- ❑ First company to partner with psychedelic pioneer, **MAPS**, on Canada's first compassionate access trial of **MDMA for PTSD**
 - ❑ MAPS-trained therapists
 - ❑ NUMI Medical Director will be the Principal Investigator
 - ❑ Trial protocol finalized and ethics and Health Canada approvals forthcoming
 - ❑ Recruitment on track to start spring/summer 2021
 - ❑ Study drug agreements are in place
 - ❑ Vancouver clinic will be used as trial testing site
- ❑ Canada's first compassionate trial of **psilocybin for substance use disorders**, with international contract research organization partner achieving progress similar to MAPS trial

Industry barriers to entry

- ❑ Limited supply of qualified clinical research teams
- ❑ Difficult to secure appropriate trial facilities and infrastructure
- ❑ Strong psychedelic research management, appropriately trained therapists and partners needed to ensure compliant operating procedures



Numinus Health

Delivers the highest quality of care to patients, using Numinus protocols and specially-trained practitioners in custom designed spaces.

Our assets

- ❑ Montreal and Vancouver locations will be offering Ketamine-Assisted Psychotherapy alongside integration and non-psychedelic services
- ❑ Vancouver clinic will also be the research site for Numinus MAPS training and compassionate access trials
- ❑ Ongoing virtual services provide flexibility in lockdown restrictions; intention to scale post-pandemic
- ❑ Plans to develop flagship centres that support community clinics in a 'hub and spoke' model
- ❑ Tailored, safe, and evidence-based treatment programs developed in consultation with clinical experts

Our progress

- ❑ Design of full range of psychedelic therapy programs, including psilocybin, ketamine and MDMA
- ❑ Design of protocols for a wide range of mental health conditions, including depression, PTSD, substance use disorder
- ❑ Active staff training underway for delivery of therapies through access to partner trainings (e.g. MAPS)
- ❑ Investing in clinic upgrades and specialized digital and physical infrastructure
- ❑ Proven acquisition and purpose-built strategies
- ❑ Real estate partner identifying and securing new locations

Industry barriers to entry

- ❑ Limited supply of qualified health care providers with sufficient psychedelic training and access to training programs
- ❑ Lengthy development and testing of protocols and programs before they can be used for patients
- ❑ Not yet standard access to supply of psychedelic medications under federal licensing requirements
- ❑ Clinic facilities must meet regulatory and clinical standards
- ❑ Strong clinical management required to ensure systems and facilities comply with multiple regulatory domains



Case study: Mindspace Acquisition

Montreal clinics clearly illustrate Numinus value proposition

- ❑ Best-in-class psychology clinic in Montreal with two locations that support 1400 clients annually through in-person and virtual services.
- ❑ Pioneer in mindfulness-based group programming and psychedelics, with recognizable brand and thought-leadership via founder Dr. Joe Flanders.
- ❑ Generated an average of 25% year-over-year growth over the past five years, including \$1.7M in revenue generation over the past 12 months.
 - ❑ Revenue anticipated to grow with the newly launched Ketamine-Assisted Psychotherapy program.

Acquisition details

- ❑ Announcement date: Dec 15, 2020
- ❑ Close date: February 8, 2021
- ❑ Numinus paid the following consideration to complete Transaction:
 - ❑ \$500,000 in cash
 - ❑ Time-based payout of 441,176 common shares of Numinus issued over 24 months
 - ❑ \$100,000 in Numinus shares, issued at Market Price, on each of the first three anniversaries of the Closing Date
 - ❑ Multi-year performance payout of \$800,000 in Numinus shares, issued at Market Price

Vital stats

- ❑ Number of therapists: 30+ mostly PhD-level psychologists
- ❑ Number of clients: 1400+
- ❑ Services offered: Psychotherapy, Psychoeducation and Group Mindfulness programming; Continuing Education for mental health professionals, including in Psychedelic-Assisted Psychotherapy
- ❑ Years in operation: 10

Future State

- ❑ New spaces designed specifically for Psychedelic-Assisted Psychotherapy
- ❑ Additional growth in psychotherapy and group-programming as in-person services resume alongside fully virtual offering initiated in 2020



IP: A stand for accessibility

Transparency and integrity in Intellectual Property

Our IP position

- ❑ Grounded in safe patient access alongside investor ROI
- ❑ Based on the understanding that molecules that were described decades ago (e.g. LSD) or compounds that occur in nature (e.g. psilocybin) cannot be patented.

Our patentable basic research

- ❑ Focused on novel laboratory discoveries and processes that are reproducible, sustainable and cost efficient.
- ❑ Supports the science that shows psychedelic effects should be embraced as part of the therapeutic experience, rather than diminished.¹


Our proprietary clinical research

- ❑ We are following an implementation science agenda to develop proprietary clinical protocols that merge decades of prior psychedelic research with clinical best practices for multiple mental disorders.
- ❑ This includes substances such as ketamine, MDMA and psilocybin for conditions such as PTSD and substance use disorders.

1. Romeo B, et al. Clinical and biological predictors of psychedelic response in the treatment of psychiatric and addictive disorders: A systematic review. J Psychiatr Res. 2021 Mar 7;137:273-282




Advancing on Strategy



Our Path Forward




1 Developing innovative therapeutics & other products



2 Developing treatment protocols, starting with ketamine, MDMA & psilocybin



3 Delivering a transformative patient experience



4 Building flagship locations & acquiring clinics that are growing, profitable and values aligned

Advocating for access, regulatory change, patient safety and open science.

Our Guiding Principles

Relationship-centric

We are committed to delivering the best client outcomes.

Thoughtful Expansion

Revenue-generating, mission-aligned clinics with strong practitioner talent and deep roots in community.

Sustainable Operations

We balance exploratory activities with ongoing revenue generation.

Collaborative Leadership

We actively ally with other leaders to raise industry standards and develop best practices.



Capitalization

CA trading symbol US trading symbol	TSX.V:NUMI OTC:LKYSF
Market capitalization	Approximately \$215M
Total shares outstanding	200,732,507
Warrants outstanding	26,580,949
Options outstanding	7,434,054
Fully diluted shares outstanding	234,747,510
Average daily volume traded (over 65 days)	TSX.V: 2,600,000 OTC: 1,000,000
Founder ownership	3.49% of shares outstanding
Cash position	\$65M

Management & Select Advisors



Payton Nyquvest
Chief Executive Officer & Co-founder

Former capital markets executive who has raised \$150M+ for public and private companies across North America. Formerly led one of Canada's largest brokerages.



Stacey Wallin
Chief Strategy Officer & Co-founder

Former founder of biotech wearables startup which scaled to serve Fortune 100 clients. Tech experience spans Canada and United States, and includes growth, scale and policy change. Founder of the Canadian Accelerator/ Incubator Network.



Dr. Evan Wood, MD, PhD
Chief Medical Officer

Medical research and policy leader specialized in substance use who works closely with Health Canada and leading institutions to inform guidelines and regulations. Established Canada's first supervised injecting site and national clinical guidelines for substance use disorders. Former Tier 1 Canada Research Chair, professor, founding Executive Director of BC Centre on Substance Use. Published 500+ scientific articles.



Michael Tan, MBA
Chief Operations Officer

Career leader in business transformation at the executive level for multinational companies, including Indigo and Hudson's Bay. Launched BC's provincial cannabis operations as first Executive Director of the BCLDB Cannabis Division.



John Fong, CPA, CGA
Chief Financial Officer

15+ years establishing global financial operations for private and public companies across mining, resources and technology. Previously led a precious metals company from exploration to commercial production in 3 years, with net income of \$100M and operating cash flow of \$98M.



Dennis McKenna, PhD
General Advisor

Legendary ethnopharmacologist, psychedelic medicine pioneer, lecturer and author. Co-founder and director of ethnopharmacology at the non-profit Heffter Research Institute.



Dr. Gabor Maté, MD, CM
Clinical Advisor

Retired physician and globally renowned thought leader sought after for expertise on trauma, addiction, stress and childhood development. International speaker, bestselling author and Order of Canada holder.



Research & Clinical Leadership



Sharan Sidhu
Science Officer & GM

Extensive experience developing strategy for research roadmaps, IP and product development. Experienced in regulatory affairs across Cannabis, Natural Health Products, Foods in North America and globally.



Dr. Devon Christie, MD
Medical Director

Family physician and Registered Therapeutic Counsellor trained by MAPS to deliver and instruct on MDMA-assisted psychotherapy for PTSD. Certified across multiple therapy modalities including ketamine-assisted psychotherapy.



Dr. Bernd O. Keller
PhD Senior Research Scientist

20+ years' experience in advanced analytical technologies and methods. Authored 30 peer reviewed publications. Former research scientist for BC Children's Hospital and director of mass spectrometry facility at Queen's University.



Dr. Kristina Grotzinger, PhD
Senior Research Scientist

20 years' phytochemistry experience in regulated lab environments. Health Canada-certified Qualified Person in Charge (QPIC). Undertaken SR&ED projects in analytical methods for cannabis testing. Avid researcher and lecturer in health/herbal medicines and author of peer-reviewed research papers.



Judy Varga, M.Sc
Head of Laboratory Operations

Analytical chemist with experience in the pharmaceutical industry. Previously GMP/GLP, QC lead with a major Canadian LP. Experienced in advanced microbiology methods.



Dr. Joe Flanders, PhD
Psychology and Therapeutic Services Director

Licensed clinical psychologist and assistant professor of psychology at McGill University. Founded Mindspace in 2011 as original owner-operator before 2021 acquisition by Numinus. Specialized in mindfulness-based therapy, with advanced certification from the University of Toronto and The Centre for Mindfulness Studies.



Dr. Elena Argento, PhD, MPH
Co-Principal Investigator, Research Scientist

Experienced in psychedelic research, including studies of naturalistic and clinical use. Collaborating with BC Centre on Substance Use on interventions for the overdose crisis. Postdoctoral Researcher at UBC. Co-Principal Investigator of Numinus Phase 2 trial of psilocybin for substance use disorders.



Dr. Lindsay Mackay, MD, CCFP
Principal Investigator

Clinician-scientist and addictions specialist physician with research training through NIDA-funded Clinical Research Fellowship, with extensive experience in the exploration of psychedelics and novel therapies as treatments for mental health and addictions. Principal Investigator of Numinus Phase 2 trial of psilocybin for substance use disorders.

Summary

A leader in psychedelic science & clinical delivery

Global clinic expansion plan, starting in Vancouver and Montreal, to deliver full suite of psychedelic offerings once regulated

Proven medical team, research, clinical and executive to drive strategy, growth and scale

Well-funded to advance research trials, therapeutics development and clinic expansion

Health Canada-licensed lab with >10 year history of botanical extraction, ongoing IP development and revenue-generating contract services

Innovation with a history of firsts

- ❑ 1st industry partner with MAPS
- ❑ 1st compassionate access trials of MDMA for PTSD and psilocybin for substance use disorders in Canada
- ❑ 1st pubco to cultivate and extract psilocybin from mushrooms

Integrated, holistic offering, generating revenue throughout the supply-to-delivery value chain



Numinus



801-33 Water Street
Vancouver, B.C. V6B 1R4
numinus.ca